• D-Luciferin Sodium Salt for Interpretable CAR-M Imaging

  2026-09-28

  D-Luciferin sodium salt enables ATP-dependent bioluminescence assays for tracking CAR-macrophage biology without confusing reporter light with therapeutic function. This guide develops an assay-design framework inspired by recent mRNA-LNP CAR-M research, emphasizing normalization, controls, and mechanistic interpretation.

• SARS-CoV-2 NSP15 Screening: Thymopentin and Oleuropein

  2026-09-28

  A 2021 structure-based virtual screen prioritized thymopentin and oleuropein as candidate binders of the SARS-CoV-2 endoribonuclease NSP15, with molecular-dynamics simulations used to examine predicted complex stability. The results provide a computational starting point for experimental testing, not evidence of antiviral efficacy or clinically validated NSP15 inhibition.

• CDK9 inhibitor A3294: Practical Protocol and QC

  2026-09-27

  CDK9 inhibitor A3294 provides a selective way to investigate CDK9-dependent transcription elongation and defined HIV-1 research workflows. Its biochemical potency and selectivity data are product-dossier values, not a substitute for cell-specific dose finding; it is not a pan-CDK reagent or evidence of broad cytotoxicity or antiviral efficacy.

• Thiazovivin: Practical ROCK Inhibitor Workflow

  2026-09-26

  Thiazovivin is a ROCK inhibitor used to support human embryonic stem cell survival after trypsinization and to improve fibroblast reprogramming efficiency in iPSC workflows. Use it as a research reagent with an empirically optimized protocol; the product information does not establish a universal dose or exposure time, and it is not for diagnostic or medical use.

• Machine Learning Designs mRNA LNPs for Microglia

  2026-09-25

  Rafiei, Shojaei, and Chau combined a 216-formulation lipid nanoparticle library with supervised machine learning to study mRNA delivery and inflammatory phenotypes in microglia. Their results identify an HA-modified formulation that delivered IL10 mRNA and reduced inflammatory readouts in cell models, while also showing that model performance depends on microglial activation state.

• Mdivi-1 in Mitochondrial Dynamics Research

  2026-09-25

  Mdivi-1 is a cell-permeable selective DRP1 inhibitor used to investigate mitochondrial fission, apoptosis, and neuroprotection. A 2026 chronic intermittent hypoxia study reports that Mdivi-1 mitigated lung apoptosis-associated changes and mitochondrial injury, while its results should be interpreted within that experimental model.

• EdU Flow Cytometry Assay Kits for Vascular Studies

  2026-09-24

  Track S-phase entry in hypoxia-responsive endothelial and smooth muscle cell models without DNA-denaturation steps. Pair EdU labeling with carefully matched controls to distinguish altered DNA synthesis from changes in cell survival or cell-cycle composition.

• Faropenem Sodium: Mechanism, Evidence & Research Use

  2026-09-24

  Faropenem sodium is a penem antibiotic described as inhibiting bacterial cell-wall synthesis and acting across Gram-positive, Gram-negative, and anaerobic bacteria. Product information reports formulation properties and antimicrobial benchmarks, while a human NPT1 study shows faropenem transport in an experimental cell system—not clinical renal clearance.

• RITA (NSC 652287): Read Drug Response Beyond IC50

  2026-09-23

  RITA (NSC 652287) offers a useful case study in why a single viability value can obscure how cancer cells respond to treatment. This article connects its reported p53 activity and DNA cross-linking with practical choices for measuring growth arrest, cell death, and response timing.

• SmD2 Acetylation and PARP Inhibitor Sensitivity in HCC

  2026-09-23

  A 2024 Nature Communications study identifies acetylation-dependent control of the spliceosome protein SmD2 as a mechanism linking alternative splicing, BRCA1/FANC expression, DNA damage repair, and PARP inhibitor response in hepatocellular carcinoma. The work supports combining HDAC-axis modulation with PARP inhibition, while indicating that spliceosome state may be an important determinant of treatment sensitivity.

• Perospirone: Separating Receptor and Kv1.5 Effects

  2026-09-22

  Perospirone and SM-9018 free base offer a powerful way to study coordinated serotonergic, dopaminergic, and vascular ion-channel pharmacology. This article presents an exposure-aware framework for distinguishing intended receptor activity from concentration-dependent Kv1.5 off-target effects in translational assays.

• CX-5461: A Mechanism-First Assay Guide

  2026-09-22

  CX-5461 is an RNA polymerase I inhibitor that connects ribosome biogenesis stress with DNA damage, mitotic catastrophe, autophagy, and senescence. This mechanism-first guide explains how to select orthogonal assays and interpret results in cancer research.

• GSK 2837808A: A Precision LDHA Tool

  2026-09-21

  GSK 2837808A is a potent lactate dehydrogenase A inhibitor for resolving how lactate flux shapes cancer-cell behavior. This article places its validated hepatocellular carcinoma activity beside the exploratory NAT1–ENO1–lactate–PD-L1 model and provides practical assay guidance.

• SmD2 Acetylation Rewires HCC PARP Sensitivity

  2026-09-21

  A 2024 Nature Communications study identifies SmD2 acetylation as a regulatory link between core spliceosome activity, BRCA1/FANC cassette-exon selection, DNA damage repair, and PARP inhibitor response in hepatocellular carcinoma. The work supports testing HDAC-axis modulation with PARP inhibition, while its model-specific findings require validation across additional tumors and drug systems.

• Plk1 Regulation of p31comet and MCC Disassembly

  2026-09-20

  This study identifies Polo-like kinase 1 (Plk1) as a direct negative regulator of p31comet-mediated mitotic checkpoint complex disassembly. Its evidence supports a phosphorylation-based mechanism in which Plk1 modifies p31comet at S102, limiting premature checkpoint inactivation during active mitosis.

8435 records 1/563 page Next 12345 下5页 Last page